|
KMID : 0366220080430030138
|
|
Korean Journal of Hematology
2008 Volume.43 No. 3 p.138 ~ p.144
|
|
|
VPDL Chemotherapy for T-cell Lymphoblastic Lymphoma (T-LBL) in Adults: Comparison with Upfront Autologous Stem Cell Transplantation in a Single Center
|
|
Yoon Dok-Hyun
Lee Dae-Ho
Huh Joo-Ryung
Lee Wook-Jin
Suh Chul-Won
Sohn Byeong-Seok
Kim Kyung-Min
Lim Sung-Nam
Kim Eun-Kyoung
Park In-Keun
Jang Geun-Doo
Kim Shin
|
|
|
Abstract
|
|
|
Background: Treatment of T-cell lymphoblastic lymphoma (T-LBL) with CHOP or CHOP-like chemotherapy
has resulted in poor long-term outcomes. High-dose chemotherapy followed by ASCT has been applied for this dreaded disease. However, the efficacy is still controversial. T-LBL is considered the nodal/extranodal presentation of acute lymphoblastic leukemia. Favorable results with VPDL chemotherapy have been reported in the setting of adult lymphoblastic leukemia. We, therefore, treated T-LBL patients with modified VPDL chemotherapy and compared the outcomes with those achieved using upfront ASCT.
Methods: We retrospectively reviewed the outcomes of 24 T-LBL patients treated either with upfront ASCT (n=11) or VPDL chemotherapy without ASCT (n=13) between January 1996 and October 2005.
Results: The median follow-up duration for surviving patients was 17 months (range, 5∼109 months). The two-year event-free survival (EFS) rates were 83.1% in the VPDL group and 27.3% in the upfront ASCT group (P=0.008). The two-year overall survival (OS) rates were 83.9% in the VPDL group and 27.3% in the upfront ASCT group (P=0.006).
Conclusion:This study suggests that VPDL chemotherapy is very effective and may be superior to upfront
ASCT in the treatment of T-LBL patients.
|
|
|
KEYWORD
|
|
|
T-cell lymphoblastic lymphoma, Chemotherapy and autologous stem cell transplantation
|
|
|
FullTexts / Linksout information
|
|
  
|
|
|
Listed journal information
|
|
  
|